196 related articles for article (PubMed ID: 34313812)
1. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound.
Karalilova RV; Batalov ZA; Sapundzhieva TL; Matucci-Cerinic M; Batalov AZ
Rheumatol Int; 2021 Oct; 41(10):1743-1753. PubMed ID: 34313812
[TBL] [Abstract][Full Text] [Related]
2. Serum YKL-40 and IL-6 levels correlate with ultrasound findings of articular and periarticular involvement in patients with systemic sclerosis.
Karalilova R; Kazakova M; Sapundzhieva T; Dichev V; Batalov Z; Sarafian V; Batalov A
Rheumatol Int; 2019 Nov; 39(11):1841-1848. PubMed ID: 31375891
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
[TBL] [Abstract][Full Text] [Related]
4. The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.
Silva C; Solanki KK; White DHN
Rheumatol Immunol Res; 2022 Jun; 3(2):84-89. PubMed ID: 36465326
[TBL] [Abstract][Full Text] [Related]
5. Subclinical dermal involvement is detectable by high frequency ultrasound even in patients with limited cutaneous systemic sclerosis.
Sulli A; Ruaro B; Smith V; Paolino S; Pizzorni C; Pesce G; Cutolo M
Arthritis Res Ther; 2017 Mar; 19(1):61. PubMed ID: 28320447
[TBL] [Abstract][Full Text] [Related]
6. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.
Khanna D; Saggar R; Mayes MD; Abtin F; Clements PJ; Maranian P; Assassi S; Saggar R; Singh RR; Furst DE
Arthritis Rheum; 2011 Nov; 63(11):3540-6. PubMed ID: 21769849
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib versus methotrexate in rheumatoid arthritis.
Lee EB; Fleischmann R; Hall S; Wilkinson B; Bradley JD; Gruben D; Koncz T; Krishnaswami S; Wallenstein GV; Zang C; Zwillich SH; van Vollenhoven RF;
N Engl J Med; 2014 Jun; 370(25):2377-86. PubMed ID: 24941177
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: A post hoc analysis of clinical trial data.
Takeuchi T; Yamanaka H; Yamaoka K; Arai S; Toyoizumi S; DeMasi R; Fukuma Y; Hirose T; Sugiyama N; Zwillich SH; Tanaka Y
Mod Rheumatol; 2019 Sep; 29(5):756-766. PubMed ID: 30489177
[No Abstract] [Full Text] [Related]
11. Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial.
Gordon JK; Martyanov V; Magro C; Wildman HF; Wood TA; Huang WT; Crow MK; Whitfield ML; Spiera RF
Arthritis Res Ther; 2015 Aug; 17(1):213. PubMed ID: 26283632
[TBL] [Abstract][Full Text] [Related]
12. Correlation between circulating fibrocytes and dermal thickness in limited cutaneous systemic sclerosis patients: a pilot study.
Ruaro B; Soldano S; Smith V; Paolino S; Contini P; Montagna P; Pizzorni C; Casabella A; Tardito S; Sulli A; Cutolo M
Rheumatol Int; 2019 Aug; 39(8):1369-1376. PubMed ID: 31056725
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
Lescoat A; Huang S; Carreira PE; Siegert E; de Vries-Bouwstra J; Distler JHW; Smith V; Del Galdo F; Anic B; Damjanov N; Rednic S; Ribi C; Bancel DF; Hoffmann-Vold AM; Gabrielli A; Distler O; Khanna D; Allanore Y;
JAMA Dermatol; 2023 Aug; 159(8):837-847. PubMed ID: 37378994
[TBL] [Abstract][Full Text] [Related]
14. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS) Register.
Hanitsch LG; Burmester GR; Witt C; Hunzelmann N; Genth E; Krieg T; Lehmacher W; Melchers I; Meurer M; Müller-Ladner U; Schulze-Lohoff E; Becker M; Sunderkoetter C; ; Riemekasten G
Rheumatology (Oxford); 2009 Jan; 48(1):70-3. PubMed ID: 19056798
[TBL] [Abstract][Full Text] [Related]
15. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.
Kuhn A; Haust M; Ruland V; Weber R; Verde P; Felder G; Ohmann C; Gensch K; Ruzicka T
Rheumatology (Oxford); 2010 Jul; 49(7):1336-45. PubMed ID: 20371505
[TBL] [Abstract][Full Text] [Related]
16. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis.
You H; Xu D; Hou Y; Zhou J; Wang Q; Li M; Zeng X
Rheumatology (Oxford); 2021 May; 60(5):2472-2477. PubMed ID: 33188425
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance is associated with digital ulcer in patients with systemic sclerosis.
Park EK; Lee SG; Kim BH; Park JH; Lee S; Kim GT
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):85-91. PubMed ID: 27383539
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.
Su TI; Khanna D; Furst DE; Danovitch G; Burger C; Maranian P; Clements PJ
Arthritis Rheum; 2009 Dec; 60(12):3821-30. PubMed ID: 19950289
[TBL] [Abstract][Full Text] [Related]
20. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease.
Junfei Z; Meihua G; Shuai Z; Xiangting L; Zhidan L; Tianming C; Yajing L; Chu T; Lipu S
Clin Rheumatol; 2023 Oct; 42(10):2823-2832. PubMed ID: 37335409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
